Pricing Log in Create free account

Agios Pharmaceuticals, Inc. (AGIO) vs Lycia Therapeutics Inc. (LYCA)

Agios Pharmaceuticals, Inc. and Lycia Therapeutics Inc. are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Lycia Therapeutics Inc. are of similar size ($1.7B and $1.7B).

Valuation

Metric AGIO LYCA Biotechnology median
P/E n/m — 10.60
P/S 12.39 — 9.40
P/B 1.78 — 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m — 0.66
EV/Sales 7.92 — 9.02
Earnings yield (21.63%) — (32.88%)
Free cash flow yield (19.26%) — (23.13%)

Profitability

Metric AGIO LYCA Biotechnology median
Gross margin 93.81% — 68.51%
Operating margin (297.72%) — 0.00%
Net margin (264.76%) — 0.00%
Free cash flow margin (238.54%) — 0.00%
Return on equity (32.95%) — (51.96%)
Return on assets (30.44%) — (46.06%)
Return on invested capital (75.02%) — 0.00%

Growth

Metric AGIO LYCA Biotechnology median
Revenue growth (TTM) 214.44% — 6.76%
EPS growth (last fiscal year) (161.17%) — 29.88%
Revenue growth, 5-year CAGR (14.45%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AGIO LYCA Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 9.69 — 4.97
Net debt to EBITDA 1.80 — 1.01

Dividend

Metric AGIO LYCA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AGIO LYCA Biotechnology median
Market cap 1.69b 1.66b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack